

Per Eystein Lonning

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/6649799/per-eystein-lonning-publications-by-year.pdf>

Version: 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

176
papers

31,624
citations

42
h-index

177
g-index

191
ext. papers

34,653
ext. citations

6.5
avg, IF

6.16
L-index

#	Paper	IF	Citations
176	C/EBPB-dependent adaptation to palmitic acid promotes tumor formation in hormone receptor negative breast cancer.. <i>Nature Communications</i> , 2022 , 13, 69	17.4	2
175	Assessing Novel Therapies Based on Late-Stage Efficacy: A Dangerous Concept?. <i>Trends in Cancer</i> , 2021 , 7, 181-185	12.5	
174	Olaparib monotherapy as primary treatment in unselected triple negative breast cancer. <i>Annals of Oncology</i> , 2021 , 32, 240-249	10.3	35
173	Polymorphisms in the TP53-MDM2-MDM4-axis in patients with rheumatoid arthritis. <i>Gene</i> , 2021 , 793, 145747	3.8	1
172	An Ultrasensitive Routine LC-MS/MS Method for Estradiol and Estrone in the Clinically Relevant Sub-Picomolar Range. <i>Journal of the Endocrine Society</i> , 2020 , 4, bvaa047	0.4	5
171	Golgi-Localized PAQR4 Mediates Antiapoptotic Ceramidase Activity in Breast Cancer. <i>Cancer Research</i> , 2020 , 80, 2163-2174	10.1	5
170	Constitutional Mosaic Epimutations - a hidden cause of cancer?. <i>Cell Stress</i> , 2019 , 3, 118-135	5.5	10
169	Evaluation of applying IHC4 as a prognostic model in the translational study of Intergroup Exemestane Study (IES): PathIES. <i>Breast Cancer Research and Treatment</i> , 2018 , 168, 169-178	4.4	1
168	White Blood Cell BRCA1 Promoter Methylation Status and Ovarian Cancer Risk. <i>Annals of Internal Medicine</i> , 2018 , 168, 326-334	8	15
167	Patterns of genomic evolution in advanced melanoma. <i>Nature Communications</i> , 2018 , 9, 2665	17.4	34
166	Buparlisib plus fulvestrant in postmenopausal women with hormone-receptor-positive, HER2-negative, advanced breast cancer progressing on or after mTOR inhibition (BELLE-3): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , 2018 , 19, 87-100	21.7	228
165	NR2F1 stratifies dormant disseminated tumor cells in breast cancer patients. <i>Breast Cancer Research</i> , 2018 , 20, 120	8.3	43
164	MDM2 promoter polymorphism del1518 (rs3730485) and its impact on endometrial and ovarian cancer risk. <i>BMC Cancer</i> , 2017 , 17, 97	4.8	13
163	The Functional Roles of the MDM2 Splice Variants P2-MDM2-10 and MDM2-B in Breast Cancer Cells. <i>Translational Oncology</i> , 2017 , 10, 806-817	4.9	1
162	Comment on "Towards a personalized approach to aromatase inhibitor therapy: a digital microfluidic platform for rapid analysis of estradiol in core-needle-biopsies" by S. Abdulwahab, A. H. C. Ng, M. D. Chamberlain, H. Ahmado, L.-A. Behan, H. Gomaa, R. F. Casper and A. R. Wheeler, <i>Lab Chip</i> , 2017 , 17, 1521-1524. <i>Lab on a Chip</i> , 2017 , 17, 2181-2187	7.2	3
161	Impact of the MDM2 splice-variants MDM2-A, MDM2-B and MDM2-C on cytotoxic stress response in breast cancer cells. <i>BMC Cell Biology</i> , 2017 , 18, 17		7
160	Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines. <i>Oncotarget</i> , 2017 , 8, 41227-41241	3.3	8

159	Prevalence of the R95* germline mutation. <i>Hereditary Cancer in Clinical Practice</i> , 2016 , 14, 19	2.3	3
158	Comments on paper: "Quantitative determination of estrone by liquid chromatography-tandem mass spectrometry in subcutaneous adipose tissue from the breast in postmenopausal women" by Vihma et al. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2016 , 159, 72	5.1	
157	Incomplete Estrogen Suppression With Gonadotropin-Releasing Hormone Agonists May Reduce Clinical Efficacy in Premenopausal Women With Early Breast Cancer. <i>Journal of Clinical Oncology</i> , 2016 , 34, 1580-3	2.2	23
156	Intra-individual genetic heterogeneity among liver metastases in metastatic colorectal cancer.. <i>Journal of Clinical Oncology</i> , 2016 , 34, 555-555	2.2	1
155	Associations between the MDM2 promoter P1 polymorphism del1518 (rs3730485) and incidence of cancer of the breast, lung, colon and prostate. <i>Oncotarget</i> , 2016 , 7, 28637-46	3.3	21
154	MDM2 promoter SNP55 (rs2870820) affects risk of colon cancer but not breast-, lung-, or prostate cancer. <i>Scientific Reports</i> , 2016 , 6, 33153	4.9	8
153	Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resection for colorectal cancer metastases. <i>International Journal of Cancer</i> , 2016 , 139, 647-56	7.5	54
152	Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo. <i>Molecular Oncology</i> , 2015 , 9, 1553-64	7.9	19
151	Normal breast tissue estrogen levels. <i>Maturitas</i> , 2015 , 81, 327	5	
150	Prognostic and predictive value of ER α and ER β in the Intergroup Exemestane Study (IES)-first results from PathIES. <i>Annals of Oncology</i> , 2015 , 26, 1890-1897	10.3	8
149	Estradiol measurement in translational studies of breast cancer. <i>Steroids</i> , 2015 , 99, 26-31	2.8	9
148	MDM4 SNP34091 (rs4245739) and its effect on breast-, colon-, lung-, and prostate cancer risk. <i>Cancer Medicine</i> , 2015 , 4, 1901-7	4.8	29
147	Genome-Wide DNA Methylation Analysis in Melanoma Reveals the Importance of CpG Methylation in MITF Regulation. <i>Journal of Investigative Dermatology</i> , 2015 , 135, 1820-1828	4.3	39
146	Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon. <i>International Journal of Cancer</i> , 2015 , 137, 96-103	7.5	24
145	The emergence of targeted drugs in breast cancer to prevent resistance to endocrine treatment and chemotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2014 , 15, 681-700	4	40
144	Effects of SNP variants in the 17 β HSD2 and 17 β HSD7 genes and 17 β HSD7 copy number on gene transcript and estradiol levels in breast cancer tissue. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2014 , 143, 192-8	5.1	7
143	TP53 status predicts long-term survival in locally advanced breast cancer after primary chemotherapy. <i>Acta Oncologica</i> , 2014 , 53, 1347-55	3.2	13
142	The multitude of molecular analyses in cancer: the opening of Pandora's box. <i>Genome Biology</i> , 2014 , 15, 447	18.3	6

141	Relationship of body mass index with aromatisation and plasma and tissue oestrogen levels in postmenopausal breast cancer patients treated with aromatase inhibitors. <i>European Journal of Cancer</i> , 2014 , 50, 1055-64	7.5	29
140	Genomic heterogeneity in primary breast cancer: Clinical implications.. <i>Journal of Clinical Oncology</i> , 2014 , 32, 11004-11004	2.2	1
139	Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649). <i>Oncotarget</i> , 2014 , 5, 8223-34	3.3	21
138	Low BRAF and NRAS expression levels are associated with clinical benefit from DTIC therapy and prognosis in metastatic melanoma. <i>Clinical and Experimental Metastasis</i> , 2013 , 30, 867-76	4.7	16
137	Lapatinib in early breast cancer--questions to be resolved. <i>Lancet Oncology, The</i> , 2013 , 14, 11-2	21.7	40
136	Mapping genetic alterations causing chemoresistance in cancer: identifying the roads by tracking the drivers. <i>Oncogene</i> , 2013 , 32, 5315-30	9.2	38
135	Ph III randomized studies of the oral pan-PI3K inhibitor buparlisib (BKM120) with fulvestrant in postmenopausal women with HR+/HER2 ⁻ locally advanced or metastatic breast cancer (BC) after aromatase inhibitor (AI; BELLE-2) or AI and mTOR inhibitor (BELLE-3) treatment.. <i>Journal of Clinical Oncology</i> , 2013 , 31, TPS650-TPS650	2.2	1
134	Glycerophosphodiester phosphodiesterase domain containing 5 (GDPD5) expression correlates with malignant choline phospholipid metabolite profiles in human breast cancer. <i>NMR in Biomedicine</i> , 2012 , 25, 1033-42	4.4	35
133	Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer. <i>Breast Cancer Research</i> , 2012 , 14, R47	8.3	49
132	Chemosensitivity and p53; new tricks by an old dog. <i>Breast Cancer Research</i> , 2012 , 14, 325	8.3	2
131	Effect of CYP19 rs6493497 and rs7176005 haplotype status on in vivo aromatase transcription, plasma and tissue estrogen levels in postmenopausal women. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2012 , 128, 69-75	5.1	13
130	P53 and its molecular basis to chemoresistance in breast cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012 , 16 Suppl 1, S23-30	6.4	51
129	Poor-prognosis estrogen receptor- positive disease: present and future clinical solutions. <i>Therapeutic Advances in Medical Oncology</i> , 2012 , 4, 127-37	5.4	22
128	Recent data on intratumor estrogens in breast cancer. <i>Steroids</i> , 2011 , 76, 786-91	2.8	26
127	Alterations of the retinoblastoma gene in metastatic breast cancer. <i>Clinical and Experimental Metastasis</i> , 2011 , 28, 319-26	4.7	12
126	Effects of the MDM2 promoter SNP285 and SNP309 on Sp1 transcription factor binding and cancer risk. <i>Transcription</i> , 2011 , 2, 207-10	4.8	33
125	RINF (CXXC5) is overexpressed in solid tumors and is an unfavorable prognostic factor in breast cancer. <i>Annals of Oncology</i> , 2011 , 22, 2208-15	10.3	31
124	Exploring breast cancer estrogen disposition: the basis for endocrine manipulation. <i>Clinical Cancer Research</i> , 2011 , 17, 4948-58	12.9	44

123	The potency and clinical efficacy of aromatase inhibitors across the breast cancer continuum. <i>Annals of Oncology</i> , 2011 , 22, 503-514	10.3	45
122	Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel. <i>PLoS ONE</i> , 2011 , 6, e19249	3.7	52
121	MDM2 promoter SNP285 and SNP309; phylogeny and impact on cancer risk. <i>Oncotarget</i> , 2011 , 2, 251-8	3.3	36
120	Intratumoral estrogen disposition in breast cancer. <i>Clinical Cancer Research</i> , 2010 , 16, 1790-801	12.9	80
119	Molecular basis for therapy resistance. <i>Molecular Oncology</i> , 2010 , 4, 284-300	7.9	36
118	Evaluation of plasma and tissue estrogen suppression with third-generation aromatase inhibitors: of relevance to clinical understanding?. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010 , 118, 288-93	5.1	11
117	Impact of aromatase inhibitors on bone health in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010 , 118, 294-9	5.1	24
116	Breast cancer aromatase expression evaluated by the novel antibody 677: correlations to intra-tumor estrogen levels and hormone receptor status. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2010 , 118, 237-41	5.1	15
115	Are current development programs realising the full potential of new agents?. <i>Breast Cancer Research</i> , 2010 , 12 Suppl 4, S23	8.3	
114	Additive endocrine therapy for advanced breast cancer - back to the future. <i>Acta Oncologica</i> , 2009 , 48, 1092-101	3.2	28
113	Molecular classes of breast cancer and their clinical relevance. <i>Current Breast Cancer Reports</i> , 2009 , 1, 183-189	0.8	
112	Nuclear receptor co-activators and HER-2/neu are upregulated in breast cancer patients during neo-adjuvant treatment with aromatase inhibitors. <i>British Journal of Cancer</i> , 2009 , 101, 1253-60	8.7	34
111	Lack of complete cross-resistance between different aromatase inhibitors; a real finding in search for an explanation?. <i>European Journal of Cancer</i> , 2009 , 45, 527-35	7.5	49
110	Tissue estradiol is selectively elevated in receptor positive breast cancers while tumour estrone is reduced independent of receptor status. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2009 , 117, 31-41	5.1	78
109	Tailored targeted therapy for all: a realistic and worthwhile objective?. <i>Breast Cancer Research</i> , 2009 , 11 Suppl 3, S7	8.3	1
108	Strength and weakness of phase I to IV trials, with an emphasis on translational aspects. <i>Breast Cancer Research</i> , 2008 , 10 Suppl 4, S22	8.3	7
107	Aromatase inhibitors: assessment of biochemical efficacy measured by total body aromatase inhibition and tissue estrogen suppression. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008 , 108, 196-202	5.1	16
106	An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2008 , 109, 90-5	5.1	54

105	Letrozole is superior to anastrozole in suppressing breast cancer tissue and plasma estrogen levels. <i>Clinical Cancer Research</i> , 2008 , 14, 6330-5	12.9	110
104	Indications and limitations of third-generation aromatase inhibitors. <i>Expert Opinion on Investigational Drugs</i> , 2008 , 17, 723-39	5.9	15
103	CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer. <i>PLoS ONE</i> , 2008 , 3, e3062	3.7	63
102	P21/WAF1 mutation and drug resistance to paclitaxel in locally advanced breast cancer. <i>International Journal of Cancer</i> , 2007 , 120, 2749	7.5	
101	Mutations and polymorphisms of the p21B transcript in breast cancer. <i>International Journal of Cancer</i> , 2007 , 121, 908-10	7.5	16
100	Breast cancer prognostication and prediction: are we making progress?. <i>Annals of Oncology</i> , 2007 , 18 Suppl 8, viii3-7	10.3	42
99	Amplification of TOP2A and HER-2 genes in breast cancers occurring in patients harbouring BRCA1 germline mutations. <i>Acta Oncologica</i> , 2007 , 46, 199-203	3.2	11
98	Trastuzumab in adjuvant breast cancer therapy. A model based cost-effectiveness analysis. <i>Acta Oncologica</i> , 2007 , 46, 153-64	3.2	43
97	Breast cancer prognostication and prediction in the postgenomic era. <i>Annals of Oncology</i> , 2007 , 18, 1293-306	10.3	46
96	Aromatase inhibitors--socioeconomical issues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2007 , 106, 55-61	5.1	1
95	Adjuvant endocrine treatment of early breast cancer. <i>Hematology/Oncology Clinics of North America</i> , 2007 , 21, 223-38	3.1	11
94	Aromatase inhibitors as adjuvant treatment of breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 2006 , 57, 53-61	7	17
93	A novel type of deletion in the CDKN2A gene identified in a melanoma-prone family. <i>Genes Chromosomes and Cancer</i> , 2006 , 45, 1155-63	5	22
92	Does adjuvant therapy with letrozole improve survival in postmenopausal women with early-stage breast cancer?. <i>Nature Clinical Practice Oncology</i> , 2006 , 3, 356-7		
91	Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2-3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer. <i>Annals of Oncology</i> , 2006 , 17, 217-25	10.3	36
90	Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study. <i>European Journal of Cancer</i> , 2006 , 42, 2968-75	7.5	87
89	Review of: Gene expression profiling identifies molecular subtypes of inflammatory breast cancer. <i>Breast Cancer Online: BCO</i> , 2006 , 9, 1-3		
88	Bone safety of aromatase inhibitors versus tamoxifen. <i>International Journal of Gynecological Cancer</i> , 2006 , 16 Suppl 2, 518-20	3.5	16

87	Letrozole (Femara) causes potent suppression of breast cancer tissue estrogen levels in the neoadjuvant setting. <i>Journal of Clinical Oncology</i> , 2006 , 24, 10532-10532	2.2	3
86	Aromatase inhibitors in the treatment of early and advanced breast cancer. <i>Acta Oncologica</i> , 2005 , 44, 23-31	3.2	18
85	Aromatase inhibitors--socio-economical issues. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 95, 137-42	5.1	3
84	Treatment with high-dose estrogen (diethylstilbestrol) significantly decreases plasma estrogen and androgen levels but does not influence in vivo aromatization in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2005 , 96, 415-22	5.1	15
83	Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer. <i>Journal of Clinical Oncology</i> , 2005 , 23, 5126-37	2.2	244
82	Exemestane for breast cancer prevention: a feasible strategy?. <i>Clinical Cancer Research</i> , 2005 , 11, 918s-24s.9	4.9	4
81	A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. <i>New England Journal of Medicine</i> , 2004 , 350, 1081-92	59.2	1500
80	Aromatase inhibitors in breast cancer. <i>Endocrine-Related Cancer</i> , 2004 , 11, 179-89	5.7	65
79	Clinical pharmacokinetics of aromatase inhibitors and inactivators. <i>Clinical Pharmacokinetics</i> , 2003 , 42, 619-31	6.2	14
78	Repeated observation of breast tumor subtypes in independent gene expression data sets. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2003 , 100, 8418-23	11.5	4262
77	Predictive value of tumour cell proliferation in locally advanced breast cancer treated with neoadjuvant chemotherapy. <i>European Journal of Cancer</i> , 2003 , 39, 438-46	7.5	41
76	Comparison between aromatase inhibitors and sequential use. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2003 , 86, 275-82	5.1	7
75	The role of aromatase inactivators in the treatment of breast cancer. <i>International Journal of Clinical Oncology</i> , 2002 , 7, 265-70	4.2	10
74	Aromatase inhibitors and inactivators for breast cancer therapy. <i>Drugs and Aging</i> , 2002 , 19, 277-98	4.7	19
73	High-dose estrogen treatment in postmenopausal breast cancer patients heavily exposed to endocrine therapy. <i>Breast Cancer Research and Treatment</i> , 2001 , 67, 111-6	4.4	194
72	Exemestane: a review of its clinical efficacy and safety. <i>Breast</i> , 2001 , 10, 198-208	3.6	14
71	Microarrays in primary breast cancer--lessons from chemotherapy studies. <i>Endocrine-Related Cancer</i> , 2001 , 8, 259-63	5.7	30
70	Resistance to endocrine therapy of breast cancer: recent advances and tomorrow's challenges. <i>Clinical Breast Cancer</i> , 2001 , 1, 297-308; discussion 309	3	17

69	Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2001 , 98, 10869-74	11.5	8341
68	Pharmacokinetics and metabolism of formestane in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 77, 39-47	5.1	20
67	Stepwise estrogen suppression manipulating the estrostat. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 2001 , 79, 127-32	5.1	16
66	Influence of TP53 gene alterations and c-erbB-2 expression on the response to treatment with doxorubicin in locally advanced breast cancer. <i>Cancer Research</i> , 2001 , 61, 2505-12	10.1	219
65	The potential for aromatase inhibition in breast cancer prevention. <i>Clinical Cancer Research</i> , 2001 , 7, 4423s-4428s; discussion 4411s-4412s	12.9	5
64	Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. <i>Journal of Clinical Oncology</i> , 2000 , 18, 2234-44	2.2	269
63	Genetic variants of CYP19 (aromatase) and breast cancer risk. <i>Oncogene</i> , 2000 , 19, 1329-33	9.2	140
62	Molecular portraits of human breast tumours. <i>Nature</i> , 2000 , 406, 747-52	50.4	11221
61	Clinico-pharmacological aspects of different hormone treatments. <i>European Journal of Cancer</i> , 2000 , 36 Suppl 4, S81-2	7.5	13
60	Pharmacology and clinical experience with exemestane. <i>Expert Opinion on Investigational Drugs</i> , 2000 , 9, 1897-905	5.9	19
59	Exemestane in breast cancer: current status and future directions. <i>Clinical Breast Cancer</i> , 2000 , 1 Suppl 1, S28-33	3	2
58	Is there a growing role for endocrine therapy in the treatment of breast cancer?. <i>Drugs</i> , 2000 , 60, 11-21	12.1	4
57	Cross-resistance to different aromatase inhibitors in breast cancer treatment. <i>Endocrine-Related Cancer</i> , 1999 , 6, 251-7	5.7	13
56	Serum homocysteine levels in postmenopausal breast cancer patients treated with tamoxifen. <i>Cancer Letters</i> , 1999 , 145, 73-7	9.9	12
55	Exemestane. <i>Drugs</i> , 1999 , 58, 681-682	12.1	
54	Pharmacological and clinical profile of anastrozole. <i>Breast Cancer Research and Treatment</i> , 1998 , 49 Suppl 1, S53-7; discussion S73-7	4.4	9
53	Pharmacological profiles of exemestane and formestane, steroidal aromatase inhibitors used for treatment of postmenopausal breast cancer. <i>Breast Cancer Research and Treatment</i> , 1998 , 49 Suppl 1, S45-52; discussion S73-7	4.4	37
52	Aromatase inhibitors and their future role in post-menopausal women with early breast cancer. <i>British Journal of Cancer</i> , 1998 , 78 Suppl 4, 12-5	8.7	15

51	Influence of treatment with aminoglutethimide on plasma and red-blood-cell glutathione status in breast cancer patients. <i>Cancer Chemotherapy and Pharmacology</i> , 1998 , 42, 46-52	3.5	3
50	Alterations in the insulin-like growth factor system during the menstrual cycle in normal women. <i>Maturitas</i> , 1998 , 28, 259-65	5	24
49	Influence of droloxifene on metastatic breast cancer as first-line endocrine treatment. <i>Acta Oncologica</i> , 1998 , 37, 365-8	3.2	15
48	In vivo inhibition of aromatization by exemestane, a novel irreversible aromatase inhibitor, in postmenopausal breast cancer patients. <i>Clinical Cancer Research</i> , 1998 , 4, 2089-93	12.9	216
47	Anastrozole--a new generation in aromatase inhibition: clinical pharmacology. <i>Oncology</i> , 1997 , 54 Suppl 2, 11-4	3.6	19
46	Influence of aminoglutethimide on plasma levels of estrone sulphate and dehydroepiandrosterone sulphate in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997 , 63, 53-8	5.1	16
45	Exemestane experience in breast cancer treatment. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997 , 61, 151-5	5.1	7
44	Plasma estrogen suppression with aromatase inhibitors evaluated by a novel, sensitive assay for estrone sulphate. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1997 , 61, 255-60	5.1	4
43	Influence of droloxifene on plasma levels of insulin-like growth factor (IGF)-I, Pro-IGF-IIe, insulin-like growth factor binding protein (IGFBP)-1 and IGFBP-3 in breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1996 , 57, 167-71	5.1	23
42	Aromatase inhibition for breast cancer treatment. <i>Acta Oncologica</i> , 1996 , 35 Suppl 5, 38-43	3.2	29
41	Insulin-like growth factors in breast cancer. <i>Acta Oncologica</i> , 1996 , 35 Suppl 5, 19-22	3.2	16
40	Influence of plasma estrogen levels on the length of the disease-free interval in postmenopausal women with breast cancer. <i>Breast Cancer Research and Treatment</i> , 1996 , 39, 335-41	4.4	44
39	Specific P53 mutations are associated with de novo resistance to doxorubicin in breast cancer patients. <i>Nature Medicine</i> , 1996 , 2, 811-4	50.5	657
38	Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer. <i>British Journal of Cancer</i> , 1996 , 74, 1286-91	8.7	282
37	Mechanisms of action of endocrine treatment in breast cancer. <i>Critical Reviews in Oncology/Hematology</i> , 1995 , 21, 158-93	7	42
36	Influence of treatment with the anti-oestrogen 3-hydroxytamoxifen (droloxifene) on plasma sex hormone levels in postmenopausal patients with breast cancer. <i>Journal of Endocrinology</i> , 1995 , 146, 359-63	4.7	21
35	Influence of droloxifene (3-hydroxytamoxifen), 40 mg daily, on plasma gonadotrophins, sex hormone binding globulin and estrogen levels in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995 , 55, 193-5	5.1	17
34	A sensitive assay for measurement of plasma estrone sulphate in patients on treatment with aromatase inhibitors. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995 , 55, 409-12	5.1	42

33	Influence of tamoxifen on sex hormones, gonadotrophins and sex hormone binding globulin in postmenopausal breast cancer patients. <i>Journal of Steroid Biochemistry and Molecular Biology</i> , 1995 , 52, 491-6	5.1	53
32	Determination of droloxifene and two metabolites in serum by high-pressure liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 1995 , 17, 259-65	3.2	12
31	Relations between sex hormones, sex hormone binding globulin, insulin-like growth factor-I and insulin-like growth factor binding protein-1 in post-menopausal breast cancer patients. <i>Clinical Endocrinology</i> , 1995 , 42, 23-30	3.4	55
30	Systemic therapy in breast cancer: efficacy and cost utility. <i>Pharmacoeconomics</i> , 1994 , 5, 198-212	4.4	16
29	Dose response evaluation. Use of plasma concentration confidence intervals as a tool to predict optimal drug dose ratio. <i>Clinical Pharmacokinetics</i> , 1993 , 25, 1-5	6.2	4
28	Use of endocrine therapy to study the biology of breast cancer. <i>Cancer Treatment Reviews</i> , 1993 , 19 Suppl B, 65-77	14.4	1
27	Aromatase inhibitors in malignant diseases of aging. <i>Drugs and Aging</i> , 1992 , 2, 530-45	4.7	11
26	Clinical pharmacokinetics of endocrine agents used in advanced breast cancer. <i>Clinical Pharmacokinetics</i> , 1992 , 22, 327-58	6.2	51
25	Influence of aminoglutethimide on plasma oestrogen levels in breast cancer patients on 4-hydroxyandrostenedione treatment. <i>Breast Cancer Research and Treatment</i> , 1992 , 23, 57-62	4.4	29
24	Influence of tamoxifen on plasma levels of insulin-like growth factor I and insulin-like growth factor binding protein I in breast cancer patients. <i>Cancer Research</i> , 1992 , 52, 4719-23	10.1	75
23	The influence of CGS 16949A on peripheral aromatisation in breast cancer patients. <i>British Journal of Cancer</i> , 1991 , 63, 789-93	8.7	70
22	Pharmacokinetics and pharmacodynamics of the aromatase inhibitor 3-ethyl-3-(4-pyridyl)piperidine-2,6-dione in patients with postmenopausal breast cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 1991 , 27, 367-72	3.5	22
21	Treatment of early breast cancer with conservation of the breast. A review. <i>Acta Oncologica</i> , 1991 , 30, 779-92	3.2	7
20	New endocrine drugs for treatment of advanced breast cancer. <i>Acta Oncologica</i> , 1990 , 29, 379-86	3.2	11
19	Aminoglutethimide enzyme induction: pharmacological and endocrinological implications. <i>Cancer Chemotherapy and Pharmacology</i> , 1990 , 26, 241-4	3.5	21
18	Postmenopausal estrogen synthesis and metabolism: alterations caused by aromatase inhibitors used for the treatment of breast cancer. <i>The Journal of Steroid Biochemistry</i> , 1990 , 35, 355-66		83
17	Decreased serum concentrations of tamoxifen and its metabolites induced by aminoglutethimide. <i>Cancer Research</i> , 1990 , 50, 5851-7	10.1	69
16	Treatment of breast cancer with aromatase inhibitors--current status and future prospects. <i>British Journal of Cancer</i> , 1989 , 60, 5-8	8.7	15

15	Alterations in the production rate and the metabolism of oestrone and oestrone sulphate in breast cancer patients treated with aminoglutethimide. <i>British Journal of Cancer</i> , 1989 , 60, 107-11	8.7	51
14	Separation of urinary metabolites of radiolabelled estrogens in man by HPLC. <i>The Journal of Steroid Biochemistry</i> , 1989 , 32, 91-7		35
13	Effects of aminoglutethimide on plasma estrone sulfate not caused by aromatase inhibition. <i>The Journal of Steroid Biochemistry</i> , 1989 , 33, 541-5		26
12	Alterations in the urine excretion of estrogen metabolites in breast cancer women treated with aminoglutethimide. <i>The Journal of Steroid Biochemistry</i> , 1989 , 33, 565-71		21
11	Plasma levels of estradiol, estrone, estrone sulfate and sex hormone binding globulin in patients receiving rifampicin. <i>The Journal of Steroid Biochemistry</i> , 1989 , 33, 631-5		16
10	Lack of diurnal variation in plasma levels of androstenedione, testosterone, estrone and estradiol in postmenopausal women. <i>The Journal of Steroid Biochemistry</i> , 1989 , 34, 551-3		25
9	Mechanisms of action of aminoglutethimide as endocrine therapy of breast cancer. <i>Drugs</i> , 1988 , 35, 685-710	1.9	90
8	Alterations in the metabolism of oestrogens during treatment with aminoglutethimide in breast cancer patients. Preliminary findings. <i>Clinical Pharmacokinetics</i> , 1987 , 13, 393-406	6.2	49
7	Accidental hypothermia. Review of the literature. <i>Acta Anaesthesiologica Scandinavica</i> , 1986 , 30, 601-13	1.9	57
6	Determination of warfarin in human plasma by high performance liquid chromatography and photodiode array detector. <i>Therapeutic Drug Monitoring</i> , 1985 , 7, 329-35	3.2	17
5	Effect of aminoglutethimide on antipyrine, theophylline, and digitoxin disposition in breast cancer. <i>Clinical Pharmacology and Therapeutics</i> , 1984 , 36, 796-802	6.1	28
4	Treatment of breast carcinoma with aminoglutethimide. <i>Acta Radiologica Oncology</i> , 1984 , 23, 421-4		15
3	Determination of aminoglutethimide and N-acetylamino glutethimide in human plasma by reversed-phase liquid chromatography. <i>Therapeutic Drug Monitoring</i> , 1984 , 6, 221-6	3.2	14
2	The relation between cell proliferation and adenylate cyclase activity in grafts of 3-methylcholanthrene induced mouse uterine cervical tumors. <i>Experientia</i> , 1982 , 38, 387-9		
1	Effect of estradiol and progesterone on the adenylate cyclase activity in grafts of 3-methylcholanthrene induced carcinomas in the mouse uterine cervix. <i>Acta Pathologica Et Microbiologica Scandinavica Section A, Pathology</i> , 1980 , 88, 111-8		